Cerba Research, Lake Success, New York.
AstraZeneca, Gaithersburg, Maryland.
Curr Protoc. 2023 Aug;3(8):e868. doi: 10.1002/cpz1.868.
Analytical method validation provides a means to ensure that data are credible and reproducible. This article will provide a brief introduction to analytical method validation as applied to cellular analysis by flow cytometry, along with practical procedures for four different types of validation. The first, Basic Protocol 1 (the limited validation protocol), is recommended for research and non-regulated laboratories. Next, Basic Protocol 2) presents a reasonable, fit-for-purpose validation approach appropriate for biopharma and research settings. Basic Protocol 3 addresses the type of validation performed in clinical laboratories for moderate-risk tests developed in house. Finally, Basic Protocol 4 describes the process that should be applied whenever a method is being transferred from one facility to another. All four validation plans follow the fit-for-purpose validation approach, in which the validation parameters are selected based on the intended use of the assay. These validation protocols represent the minimal requirement and may not be applicable for every intended use such as high-risk clinical assays or data to be used as a primary endpoint in a clinical trial. The recommendations presented here are consistent with the white papers published by the American Association of Pharmaceutical Scientists and the International Clinical Cytometry Society, as well as with Clinical Laboratory Standards Institute Guideline H62: Validation of Assays Performed by Flow Cytometry (CLSI, 2021). © 2023 Wiley Periodicals LLC. Basic Protocol 1: Limited validation Basic Protocol 2: Fit-for-purpose validation for biopharma and research settings Basic Protocol 3: Validation for moderate clinical risk laboratory developed tests Basic Protocol 4: Transfer validation.
分析方法验证提供了一种确保数据可信和可重现的手段。本文将简要介绍应用于流式细胞术进行细胞分析的分析方法验证,并提供四种不同类型验证的实用程序。第一种,基本方案 1(有限验证方案),推荐用于研究和非监管实验室。接下来,基本方案 2)提出了一种合理的、适用于生物制药和研究环境的有针对性的验证方法。基本方案 3 介绍了在内部开发的中等风险测试的临床实验室中进行的验证类型。最后,基本方案 4 描述了每当方法从一个设施转移到另一个设施时应应用的过程。所有四个验证计划都遵循有针对性的验证方法,其中验证参数是根据测定的预期用途选择的。这些验证方案代表了最低要求,可能不适用于每个预期用途,例如高风险临床测定或用作临床试验主要终点的数据。这里提出的建议与美国药物科学家协会和国际临床细胞化学协会发布的白皮书以及临床实验室标准协会指南 H62:流式细胞术测定的验证(CLSI,2021 年)一致。©2023 年 Wiley 期刊 LLC. 基本方案 1:有限验证 基本方案 2:适用于生物制药和研究环境的有针对性的验证 基本方案 3:中等临床风险实验室开发测试的验证 基本方案 4:转移验证。